Related Experiment Video

Updated: Nov 29, 2025

A Mouse Model of Vascularized Heterotopic Spleen Transplantation for Studying Spleen Cell Biology and Transplant Immunity
08:04

A Mouse Model of Vascularized Heterotopic Spleen Transplantation for Studying Spleen Cell Biology and Transplant Immunity

Published on: June 11, 2019

16.5K

Splenectomy before allogeneic hematopoietic stem-cell transplantation for myelofibrosis: Tumor burden matters!

Vincent T Ho1, Alessandro Rambaldi2

  • 1Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.

American Journal of Hematology
|November 21, 2020
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Application of Microwave Ablation in Laparoscopic Partial Splenectomy
03:49

Application of Microwave Ablation in Laparoscopic Partial Splenectomy

Published on: November 15, 2024

371
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.5K

Related Experiment Videos

Last Updated: Nov 29, 2025

A Mouse Model of Vascularized Heterotopic Spleen Transplantation for Studying Spleen Cell Biology and Transplant Immunity
08:04

A Mouse Model of Vascularized Heterotopic Spleen Transplantation for Studying Spleen Cell Biology and Transplant Immunity

Published on: June 11, 2019

16.5K
Application of Microwave Ablation in Laparoscopic Partial Splenectomy
03:49

Application of Microwave Ablation in Laparoscopic Partial Splenectomy

Published on: November 15, 2024

371
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.5K

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

652
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
652
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.4K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.4K

Articles linked to this work by shared authors, journal, and citation graph.

iMTSS: an integrated framework for biology- and patient-driven prognosis in myelofibrosis undergoing transplantation.

Transplantation and cellular therapy·2026

Long-term results of the HD0607 trial on interim PET-adapted treatment of advanced-stage Hodgkin lymphoma beyond 10 years of follow-up.

EClinicalMedicine·2026

Radiation-Free Therapy for the Initial Treatment of Good Prognosis Early Non-Bulky Hodgkin Lymphoma, Defined by a Low Metabolic Tumor Volume and a Negative Interim PET After 2 Chemotherapy Cycles: The RAFTING Trial Protocol.

Biomedicines·2026

Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).

British journal of haematology·2026

Interindividual HLA evolutionary divergence in mismatched unrelated donor allo-HCT for malignant hematological disorders.

Blood advances·2026

Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.

British journal of haematology·2026

Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk-Stratified Analysis in 540 Patients.

American journal of hematology·2026

Hairy Cell Leukemia: 2026 Update on Diagnosis, Risk-Stratification, and Treatment.

American journal of hematology·2026

Splenic Tropism and Spleen-Modulated Systemic Inflammation in Acute Plasmodium vivax Malaria.

American journal of hematology·2026

The Presence and Percentage of Circulating Nucleated Red Blood Cells Reveal Distinct Characteristics in Adults With Sickle Cell Disease.

American journal of hematology·2026

Anticoagulant Therapy and Bleeding-Related Hospitalizations in Patients With Cancer: A National Cohort Study.

American journal of hematology·2026

Phase II Study of Posttransplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After HLA-Mismatched Unrelated Donor Reduced Intensity Transplantation: Results From the ACCESS Trial Expansion Cohort.

American journal of hematology·2026

Association of Time of Day With Functional Outcome in Intracerebral Hemorrhage.

European journal of neurology·2026

Development of CRISPR_SCD001, an Autologous Hematopoietic Stem Cell Gene Therapy for Sickle Cell Disease after CRISPR-Cas9 Mediated Correction.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Prognostic value of the HALP (hemoglobin, albumin, lymphocyte, and platelet) score in emergency versus elective inguinal hernia repair: A retrospective study.

Medicine·2026

Comparing Three Scoring Models for Predicting Unruptured Intracranial Aneurysm Progression in Subarachnoid Hemorrhage Patients with Multiple Intracranial Aneurysms.

Academic radiology·2026

Association of time of day at stroke onset with functional outcomes after reperfusion therapy in acute ischaemic stroke: a retrospective cohort study in China.

BMJ open·2026

A new player in hemolytic uremic syndrome: the plasma kallikrein-kinin system, a target of heme.

Kidney international·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us